GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of NVAX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Thursday for Novavax
(Updated on Apr 18, 2024)

Sell candidate since Apr 10, 2024 Loss -8.69% PDF

No changes to the price of Novavax stock on the last trading day (Thursday, 18th Apr 2024). During the last trading day the stock fluctuated 4.59% from a day low at $3.81 to a day high of $3.99. The price has fallen in 7 of the last 10 days and is down by -12.39% for this period.

The stock has broken the very wide and weak rising short-term trend down. This signalizes a slower rate of rising, but may also be an early warning about a possible trend shift. Due to the trend being broken there will now be resistance at the bottom line of the trend at $3.90. A reaction back to this level may hold a second chance to get out before further falls.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

NVAX Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, April 17, 2024, and so far it has fallen 0%. Further rise is indicated until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Novavax stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.10 and $4.78. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day while price remained unchanged. This may be an early warning, but it may also not. We still recommend that you pay attention over the next couple of days.

Support, Risk & Stop-loss for Novavax stock

Novavax finds support from accumulated volume at $3.79 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.175 between high and low, or 4.59%. For the last week, the stock has had daily average volatility of 5.31%.

Novavax is oversold on RSI14 (6). Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (NVAX) For The Upcoming Trading Day Of Friday 19th

For the upcoming trading day on Friday, 19th we expect Novavax Inc to open at $3.90, and during the day (based on 14 day Average True Range), to move between $3.63 and $4.15, which gives a possible trading interval of +/-$0.262 (+/-6.74%) up or down from last closing price. If Novavax Inc takes out the full calculated possible swing range there will be an estimated 13.48% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $3.93 (1.03%) than the support at $3.79 (2.57%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Novavax Inc stock A Buy?

The Novavax stock holds several negative signals and despite the positive trend, we believe Novavax will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -3.512 Sell Candidate Unchanged

Predicted Opening Price for Novavax Inc of Friday, April 19, 2024

Fair opening price April 19, 2024 Current price
$3.90 ( 0.129%) $3.89

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for NVAX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.07 4.63 %
R2 4.00 2.91 %
R1 3.96 1.85 %
Current price: 3.89
Support S1 3.83 -1.59 %
S2 3.79 -2.65 %
S3 3.72 -4.37 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 4.41 13.37 %
R2 4.03 3.60 %
R1 3.93 1.03 %
Current price 3.89
Support S1 3.79 -2.57%
S2 3.78 -2.83%
S3 3.76 -3.34%

FAQ

What is the symbol for Novavax Stock and on which exchange is it traded?
The symbol for Novavax is NVAX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Novavax Stock?
The Novavax stock holds several negative signals and despite the positive trend, we believe Novavax will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Novavax Stock?
Novavax Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Novavax Stock.

What's the current price of Novavax Stock?
As of the end of day on the 2024-04-18, the price of an Novavax (NVAX) share was $3.89.

What is the 52-week high and low for Novavax Stock?
The 52-week high for Novavax Stock is $11.36 and the 52-week low is $3.53.

What is the market capitalization of Novavax Stock?
As of the 2024-04-18, the market capitalization of Novavax is 544.417M.

When is the next earnings date for Novavax?
The upcoming earnings date for Novavax is May 14, 2024.
Click to get the best stock tips daily for free!

About Novavax Inc

Novavax Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria... NVAX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT